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Abstract
Introduction: Immune thrombotic thrombocytopenic purpura (iTTP) is a rare disorder caused by acquired autoantibodies 
to a disintegrin and metalloprotease with thrombospondin-1 motifs (ADAMTS-13) that normally cleaves von Willebrand 
factor macromolecules. It is manifested by microangiopathic hemolytic anemia, systemic microvascular thrombi forma-
tion, and subsequent end-organ ischemia (renal and neurological manifestations). Early diagnosis and management 
resulted in improving the survival rate. This is a retrospective study conducted to describe the clinical characteristics of 
patients diagnosed with iTTP, their survival, and prognostic factors affecting it.
Methods: We included adult patients who met the diagnostic criteria of iTTP between 2016 and 2019. Based on PLAS-
MIC score for TTP, our patients ranged from 6 to 7. ADAMTS-13 testing was not done because of financial issues.
Results: A total of 21 patients were included in this study. The median age of the studied patients was 30.45 years, and 
81% of them were female. The most common clinical feature was fever (57.1%), followed by bleeding manifestations 
(52.4%), neurological manifestations (47.6%), renal impairment (42.9%), and cardiac manifestations (9.5%). There 
were a total of 4 deaths (19.04%). The overall survival was correlated significantly with neurological manifestations and 
PLASMIC scores (p =0.02, 0.012, respectively).
Conclusions: Our report reinforces that iTTP is not mandatory to be presented with classic pentad. Using PLASMIC 
score could help in the diagnosis and prediction of survival, and we strongly suggest that the absence of neurological 
manifestations results in better overall survival. Therapeutic plasma exchange should be started as soon as possible 
once iTTP is suspected. Rituximab has an important role in improving treatment outcomes.
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Introduction
Thrombotic thrombocytopenic purpura (TTP) is a life-
-threatening thrombotic microangiopathy associated with 
a severe deficiency in ADAMTS13 (a disintegrin and me-
talloprotease with thrombospondin-1 motifs; 13th member 
of the family), the enzyme that cleaves the ultra-large von 
Willebrand factor (vWF) multimers in human’s plasma [1]. 
ADAMTS-13 deficiency is caused by a mutational defect in 
the ADAMTS-13 gene (congenital TTP) or immune-mediated 
(iTTP) by circulating autoantibodies against ADAMTS-13 
that may be associated with a prior immune “trigger” such 
as pregnancy, history of infection, systemic disorders, and 
drugs [2]. iTTP is more common in the 4th decade, with 
female to male ratio of 3:2 [3]. TTP must be suspected 
and confirmed by laboratory testing following its clinical 
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intermediate-risk (5), and high-risk (6–7). Internal and ex-
ternal validation studies revealed that the frequency of se-
vere ADAMTS-13 deficiency is 0–4%, 5–24%, and 62–82% 
in all risk categories, respectively [10].
Treatment response was defined according to inter-
national recommendations as a complete response (CR), 
which was defined as the absence of any clinical manife-
stations and normalization of platelet count for ≥2 days. 
No doubling of platelet count after four days of standard 
intensive therapy and persistently high LDH levels was con-
sidered as a refractory disease. Relapse was the reappe-
arance of clinical features of iTTP for at least 2 days [11].
Statistical analysis
Data were analyzed on a personal computer running 
SPSS21 for Windows (Statistical Package for Social Scien-
tists) Release 18. A 2-tailed p-value of <0.05 was stati-
stically significant. For descriptive statistics of qualitative 
variables, the frequency distribution procedure was run with 
the calculation of the number of cases and percentages. 
For descriptive statistics of quantitative variables, mean, 
standard deviation (SD), and range were used to describe 
the central tendency and dispersion as appropriate. The ove-
rall survival was estimated through the Kaplan-Meier test.
Results
This study was conducted on 21 patients. The mean age 
of the studied patients was 30.45 years, and 81% of them 
were female. The most common clinical feature was fever 
(57.1%), followed by bleeding manifestations (52.4%), 
neurological manifestations (47.6%) in form of headache, 
slurred speech, seizures, confusion up to coma, renal 
impairment (42.9%), and cardiac manifestations (9.5%) in 
form of arrhythmia and myocardial infarction. The mean va-
lues at presentation were consistent with microangiopathic 
hemolytic anemia (Table II).
presentation. The “classical” pentad that includes throm-
bocytopenia, MAHA, fever, renal failure, and neurological 
manifestations is uncommon. Gastrointestinal symptoms, 
such as vomiting, diarrhea, and abdominal pain are fre-
quent; however, myocardial ischemia, pancreatitis, and 
less commonly, a pulmonary injury may also occur [3, 4].
Advanced age, cardio-vascular system affection, and 
high lactate dehydrogenase (LDH) values have been cor-
related with high mortality risk. Management of iTTP invol-
ves proceeding safely and quickly initiating the immunomo-
dulating agents targeting the lymphocytes responsible for 
autoantibodies production alongside a treatment backbo-
ne of therapeutic plasma exchange (TPEx), which helps to 
replete ADAMTS-13 and remove vWF and autoantibodies 
[5]. Untreated iTTP is associated with mortality as high as 
90%; with TPEx, mortality can be reduced to 20% [6]. ISTH 
guidelines recommend using corticosteroids in addition to 
TPEx for treatment of first acute episode and relapses of 
iTTP. Meanwhile, adding rituximab will be effective in the 
treatment of known comorbid autoimmune disease [7].
Recently, caplacizumab (anti-vWF nanobody), blocks the 
adhesion of platelets to vWF and prevents the formation of 
microvascular thrombi [8]. It is recommended to be used 
early at the time of an acute TTP event. However, it neither 
corrects the level of plasma ADAMTS-13 nor does it suppress 
the autoantibodies to ADAMTS-13. Thus, other immunosu-
ppressive therapies use steroids and rituximab that are still 
required to control the underlying disease process [7–9].
In this study, we demonstrate the basic clinic-patholo-
gical features of TTP patients emphasizing the pattern and 
outcome of the disease.
Material
Patients and methodology
All data from iTTP patients referred to Oncology Center and 
Mansoura University from 2016 to 2019 were analyzed. 
We diagnosed our cases based on negative coombs test 
hemolytic anemia and found the presence of schistocy-
tes in peripheral blood film stained with Leishman stain, 
acute peripheral thrombocytopenia (<150 ×103/mm3), 
reticulocyte counting by brilliant cresyl blue staining plus 
or minus the rest of the characteristic pentad. A workup 
including history, physical examination, radiological stu-
dies, serum LDH, liver function, renal function test, viral 
marker, antinuclear antibody, anti-double-stranded DNA 
antibody to exclude secondary causes of iTTP as drugs, 
pregnancy, autoimmune diseases, malignancies, HIV, and 
other infections. ADAMTS-13 testing was not done because 
of financial issues.
We retrospectively applied the PLASMIC score to stra-
tify the cases (Table I). The PLASMIC score is a seven-
-item score with one point is assigned for each item. The 
risk stratification categories are as follows: low-risk (0–4), 
Table I. PLASMIC scoring system
Variables Points
Platelet count <30 ×109/L 1
Hemolysis present:
• reticulocyte count >2.5%, or
• haptoglobin undetectable, or
• indirect bilirubin >2.0 mg/dL
1
No active cancer 1
No history of solid organ or stem cell transplant 1
Mean corpuscular volume (MCV) <90 1
International normalized ratio (INR) <1.5 1
Creatinine <2.0 mg/dL 1
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The patients were administered with steroids and TPEx 
for treatment, and the average number of sessions was 
15 (range 2–45 sessions). Seven patients required ritu-
ximab, 6 of them received it at presentation, and it was 
administered as the second line in one patient; 47.62% 
of patients required cyclosporine as second or third line. 
There were 4 deaths (19.04%), 2 of them were related to 
relapse and the other 2 were secondary to refractoriness 
to therapy.
The mean overall survival of the studied patients was 
19.84 months [95% (confidence interval) CI: 16.41–23.55]. 
The patients presented with a PLASMIC score 6 and the 
absence of neurological problems were associated with 
better overall survival compared to other groups with sig-
nificant p =0.012, 0.02, respectively compared with other 
groups as shown figures 1 and 2, while overall survival in-
significantly correlated with age >30 years (p =0.1), fever 
(p =0.42), and renal impairment (p =0.38).
Discussion
Thrombotic thrombocytopenic purpura’s diagnosis is chal-
lenging secondary to its variable clinical presentations, 
which could overlap with other thrombotic microangio-
pathies and the unavailability of ADAMTS13 tests [12]. 
Many diagnostic scores are available such as the PLASMIC 
score, which is considered a useful application; as it has 
been able to diagnose TTP associated with ADAMTS-13 
deficiency practically and statistically accurate, it’s of low-
-cost, fast, especially in developing countries [10]. Other 
scores as the French registry-based score (Table III) and the 
one proposed by Bentley et al. are also available [13, 14].
In this study, we review the clinical presentations and 
laboratory tests for TTP. We also used the PLASMIC score 
to retrospectively assess our patients.
Our data revealed that females represented 81% of the 
studied cases, with a mean age of 30.45 ±9 years. The most 
Table II. Basic descriptive date of studied group
Parameters Mean ± SD




WBC ×109/L 10.42 ± 6.58
Hb [g/dL] 7.31 ± 1.43
Platelets ×109/L 33.9 ± 24.11
Reticulocyte count [%] 5.5% ± 2.6%
Schistocytes cells [%] 6.14% ± 2.26%
Liver function 
test
SGPT 44.9 ± 38.12
SGOT 64.14 ± 60.9
Total bilirubin  
[mg/dL]
2.81 ± 1.05



















Renal impairment 9 (42.9%)





SD — standard deviation; WBC —  white blood cells; Hb — hemoglobin; SGPT — serum glutamic-
-pyruvic transaminase; SGOT — serum glutamic-oxaloacetic transaminase; LDH — lactate dehy-
drogenase
Figure 1. Effect of PLASMIC score on overall survival (OS) of stud-
ied cases
OS





























Figure 2. Effect of neurological (neuro) manifestations on overall 
survival (OS) of studied cases
OS
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common feature in our study was fever (57.1%), followed 
by bleeding manifestations (52.4%), neurological manife-
stations (47.6%) in form of headache, slurred speech, se-
izures, confusion up to coma, renal impairment (42.9%), 
and lastly cardiac manifestations (9.5%).
Meanwhile, an Omanian study conducted on 38 TTP pa-
tients revealed that the patients’ mean age was 36 years, 
66% of patients were females. Their clinical presentation 
was: fever (63%), renal impairment (50%), bleeding (31%), 
fits (21%), high blood pressure reading (21%), headache 
(15%), confusion (15%), postpartum presentation (15%) 
and stroke (7.9%) [15].
In comparison to the review from Oklahoma TTP-HUS Re-
gistry that studied 78 patients with acquired TTP, gastrointe-
stinal symptoms were found recorded in 69%, weakness in 
63%, bleeding or purpura in 54%, major neurological findings 
including (coma, stroke, transient focal abnormalities, and 
seizures) were recorded in 41% of patients, while minor neu-
rological findings including (confusion and headache) were 
found in 26% of patients and fever with chills in 10% [16, 17].
Focusing on neurological and renal affection in TTP 
patients, their pathogenesis is mainly caused by the de-
position of hyaline thrombi widely with fibroblastic infiltra-
tion and endothelial overlay found in the terminal arterio-
les and capillaries of multi-organs. Pre-occlusive pseudo-
-aneurysmal dilatation may be one of the mechanisms. 
These mechanisms explain the severity of these events in 
TTP patients and their consideration as independent risk 
factors for prognosis [18].
We retrospectively stratified our iTTP patients based on 
the PLASMIC score, and all of them were categorized as 
a high-risk group, 12 patients (57.1%) were with a score of 
6 and 9 patients (42.9%) were with a score of score 7. The 
PLASMIC score was developed and validated by a study con-
ducted on 214 cases in the Harvard Thrombotic Microangio-
pathies Research Collaborative Registry [10]. In addition, the 
100% diagnostic accuracy for PLASMIC score was confirmed 
by a study conducted in eight patients with iTTP, 4 cases 
with ADAMTS-13 activity <10%, had a PLASMIC score of 6. 
The other 4 had ADAMTS-13 activity >10%, had a <6 score. 
Also, the PLASMIC score predicted accurately their respon-
se to TPEx and the risk of long-term poor outcomes [19].
However, Prevel and his colleagues [5] provide evidence 
that the diagnosis of iTTP based on clinical scores aimed 
at predicting a severe ADAMTS-13 deficiency may be less 
accurate among older patients as organ damage in older 
patients following microthrombi formation may develop 
earlier than in younger patients, leading to earlier clinical 
manifestations with older age. In contrast, the organs of 
younger patients could tolerate microthrombi and ischemia, 
which leads to more aggressive cytopenias.
Steroids and TPEx were used for treatment, and the 
average number of sessions was 15; (range 2–45 ses-
sions). Seven patients required rituximab, 6 of them re-
ceived it at presentation, and it was administrated as the 
second line in one patient, 47.62% of patients required cyc-
losporine as the second or third line. There were 4 deaths 
(19.04%), 2 of them were related to relapse and the other 
2 were secondary to refractoriness to therapy. However, 
we noticed that using rituximab as the first line in addition 
to TPEx and steroids improved the survival of our patients 
who had neurological manifestation at presentation.
Rituximab is a monoclonal IgG1ĸ antibody, which is com-
monly used in treatment regimens for iTTP. Rituximab can 
prevent relapse and reduce mortality. Its half-life is about 
2 to 3 weeks but ultimately depends on the underlying tre-
ated condition, presence of TPEx, and CD20+ lymphocyte 
load [20, 21]. A prospective study by Carden et al. 2020 [22] 
conducted on three patients studying the role of rituximab 
in iTPP, found that rituximab can eliminate all circulating 
CD20+ B and T cells within 24 hours for each patient, despi-
te uninterrupted daily TPEx through multiple mechanisms, 
including antibody-dependent cell-mediated cytotoxicity, 
complement-dependent cytotoxicity, and apoptosis.
Data revealed that the mean overall survival of our pa-
tients was 19.84 months (95%CI: 16.41–23.55). Patients 
presented with PLASMIC score 7 and absence of neurolo-
gical manifestations were associated with better overall 
survival with significant p =0.012 and 0.02, respectively, 
compared with the other groups, while the overall survival 
insignificantly correlated with age, fever and renal impair-
ment (p =0.1, 0.42, and 0.38, respectively). Similarly, it 
was reported in a study from the UK TTP Registry involving 
292 patients that 24% of the patients who presented with 
a reduced Glasgow Coma Score were significantly asso-
ciated with shorter overall survival compared to the other 
groups (p <0.0001) [23].
A study conducted by Prevel et al. [5] on 411 patients 
showed that for patients aged more than 60 years, renal 
impairment; cardiac involvement, and total TPEx volume 
were independently associated with mortality. That is why 
physicians should be aware of atypical clinical presenta-
tions and for immediate intervention once suspected, which 
could improve the prognosis in iTTP patients.
Conclusion
The high cost of ADAMTS-13 testing makes it infeasible 
to do it for all patients in our country, and that is why we 
retrospectively applied the PLASMIC score trying to validate 
Table III. The French score — modified
Variables Points
Platelet count <3 ×1010/L 1
Creatinine >2.26 mg/dL 1
Reactive antinuclear antibodies 1
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it in our community. A high PLASMIC score indicates imme-
diate TPEx without losing time waiting for ADAMTS-13 level, 
while a low score, synchronized with low clinical probability, 
justifies further search for an alternate diagnosis in order 
to avoid overuse and associated complications of TPEx. We 
also aimed to focus the spot on neurological presentation 
of TTP patient correlating with worse survival and this may 
be put into consideration as a risk factor during deciding 
the treatment plan.
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